116 related articles for article (PubMed ID: 9744775)
1. Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice.
Wright JE; Pardo M; Tretyakov A; Alperin WL; Trites D; Rosowsky A
Cancer Chemother Pharmacol; 1998; 42(4):300-6. PubMed ID: 9744775
[TBL] [Abstract][Full Text] [Related]
2. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
3. Analogues of N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation.
Rosowsky A; Vaidya CM; Bader H; Wright JE; Teicher BA
J Med Chem; 1997 Jan; 40(3):286-99. PubMed ID: 9022795
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Rosowsky A; Bader H; Wright JE; Keyomarsi K; Matherly LH
J Med Chem; 1994 Jul; 37(14):2167-74. PubMed ID: 8035423
[TBL] [Abstract][Full Text] [Related]
5. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
6. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine.
Rosowsky A; Wright JE; Vaidya CM; Forsch RA
Pharmacol Ther; 2000 Mar; 85(3):191-205. PubMed ID: 10739874
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
[TBL] [Abstract][Full Text] [Related]
8. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
9. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase.
Johnson JM; Meiering EM; Wright JE; Pardo J; Rosowsky A; Wagner G
Biochemistry; 1997 Apr; 36(15):4399-411. PubMed ID: 9109647
[TBL] [Abstract][Full Text] [Related]
10. Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.
Wright JE; Vaidya CM; Chen Y; Rosowsky A
Biochem Pharmacol; 2000 Jul; 60(1):41-6. PubMed ID: 10807943
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro antitumor activity of new deaza analogues of the nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523).
Vaidya CM; Wright JE; Rosowsky A
J Med Chem; 2002 Apr; 45(8):1690-6. PubMed ID: 11931624
[TBL] [Abstract][Full Text] [Related]
12. Analogues of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity.
Rosowsky A; Wright JE; Vaidya CM; Forsch RA; Bader H
J Med Chem; 2000 Apr; 43(8):1620-34. PubMed ID: 10780919
[TBL] [Abstract][Full Text] [Related]
13. PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates.
Rosowsky A
Curr Med Chem; 1999 Apr; 6(4):329-52. PubMed ID: 10101216
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss.
Kaufman Y; Ifergan I; Rothem L; Jansen G; Assaraf YG
Blood; 2006 Apr; 107(8):3288-94. PubMed ID: 16368880
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
van der Heijden JW; Assaraf YG; Gerards AH; Oerlemans R; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Scand J Rheumatol; 2014; 43(1):9-16. PubMed ID: 23987246
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.
Cody V; Galitsky N; Luft JR; Pangborn W; Rosowsky A; Blakley RL
Biochemistry; 1997 Nov; 36(45):13897-903. PubMed ID: 9374868
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
[TBL] [Abstract][Full Text] [Related]
19. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Norris RE; Adamson PC
Cancer Chemother Pharmacol; 2010 May; 65(6):1125-30. PubMed ID: 19784838
[TBL] [Abstract][Full Text] [Related]
20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
